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 Mon1 is an evolutionarily conserved gene that has homologs from yeast to 
humans.  The original identification and characterization of Mon1 in mammals, Mon1a, 
was performed in a study that identified Mon1a as a modifier of iron homeostasis in 
mice.  That work demonstrated that C57BL mice harbor an intrinsic “gain-of-function” 
mutation that resulted in an excess of the iron exporter ferroportin at the cell surface of 
iron recycling macrophages.  The study also showed that Mon1a had a function in the 
movement of soluble and membrane-bound proteins through the secretory apparatus.  We 
were able to expand on those findings using protein interaction and RNAi analysis to 
demonstrate that Mon1a associates with the molecular motor Dynein, known to function 
in ER-Golgi trafficking.  Subcellular localization demonstrated that Mon1a peripherally 
associates with the ER membrane.  Further, RNAi-mediated reduction of Mon1a resulted 
in a significant decrease in the formation of ER-derived vesicle, which resulted in 
impaired trafficking in the early secretory pathway.  We also determined that the 
movement of the viral protein VSVGtsGFP from the Golgi to the plasma membrane was 
delayed in Mon1a-depleted cells. 
 A yeast two-hybrid (Y2H) analysis of Mon1a interacting partners found that a F-
BAR domain-contain protein, FCHo2, known to affect membrane traffic at the cell 
surface, physically associated with Mon1a.  RNAi-mediate reduction of Mon1a or 
 iv 
FCHo2 resulted in severe Golgi fragmentation, which was dependent on the activity of 
the Golgi GTPase Rab6.  The RNAi-mediate phenotypes of Mon1a and FCHo2 were not 
identical as only FCHo2 silencing-induced Golgi fragmentation was cell cycle-
dependent.  We show using FRAP analysis that FCHo2 is necessary for the lateral 
movement of membrane proteins between Golgi elements that link Golgi cisternae.  We 
determined that FCHo2-mediated Golgi fragmentation resulted in immature glycosylation 
moieties at the plasma membrane.  This dissertation describes novel roles for both Mon1a 






























1.  INTRODUCTION ................................................................................................1 
 
1.1 Identification of Mon1a: a membrane traffic regulator that affects iron 
metabolism .................................................................................................... 4 
1.2 Identification of Mon1 in yeast ..................................................................... 5 
1.3 The role of SAND-1/Mon1a/b in the endocytic pathway ............................. 7 
1.4 ER-derived vesicle formation ....................................................................... 9 
1.5 References ..................................................................................................... 11 
 
2.  MON1A PROTEIN ACTS IN THE SECRETORY APPARATUS .................... 14 
 
2.1 Abstract ......................................................................................................... 15 
2.2 Introduction ................................................................................................... 15 
2.3 Experimental Procedures .............................................................................. 15 
2.4 Results........................................................................................................... 17 
2.5 Discussion ..................................................................................................... 24 
2.6 References ..................................................................................................... 26 
 
3.  MON1A AND FCHO2 ARE REQUIRED FOR GOLGI ARCHITECTURE 
MAINTENANCE .................................................................................................. 27 
 
3.1 Introduction ................................................................................................... 27 
3.2 Experimental Procedures .............................................................................. 28 
3.3 Results........................................................................................................... 32 
3.4 Discussion ..................................................................................................... 50 
3.5 References ..................................................................................................... 53 
 
4.  CONCLUSIONS AND FUTURE DIRECTIONS ............................................... 55 
 
4.1 Mon1a function in the secretory pathway .................................................... 55 
 vii 
4.2 Organelle maintenance ................................................................................. 57 
4.3 Future directions ........................................................................................... 60 
4.4 Mitochondrial maintenance in FCHo2-depleted cells .................................. 60 
4.5 Golgi-ER retrograde trafficking ................................................................... 61 
4.6 Consequences of the allelic status of Mon1a ................................................ 64 











2.1  Trafficking of VSVG-GFP is delayed in Mon1a-silenced cells .........................18 
 
2.2  Reductions in Mon1a alter Golgi morphology  ..................................................19 
 
2.3  Reductions in Mon1a affect trafficking from the ER to the Golgi .....................20 
 
2.4  Mon1a is a cytosolic protein that peripherally associates with the ER ...............21 
 
2.5  FLAG-Mon1a interacts with Dynein and reductions in DHC1 delay trafficking  
from ER to Golgi ................................................................................................22 
 
2.6  Volocity analysis and quantification of changes Golgi morphology in silenced  
cells .....................................................................................................................22 
 
2.7  Reductions in Mon1a or DHC1 affect steady state Golgi and ERGIC-53  
morphology ........................................................................................................23 
 
2.8  Silencing Mon1a delays formation of ERGIC-53-positive vesicles off the  
ER .......................................................................................................................24 
 
2.9  Model of Mon1a and Dynein acting in vesicle formation off the ER ................25 
 
3.1  Mon1a dimerization and associates with the endocytic F-BAR protein  
FCHo2 ................................................................................................................34 
 
3.2  FCHo2 is required for maintenance of Golgi architecture..................................36 
 
3.3  FCHo2 is not required for ER-Golgi transport ...................................................37 
 
3.4  siRNA targeting 5’-UTR of Mon1a fragments the Golgi apparatus...................40 
 
3.5  Mon1a (5’-UTR) and FCHo2 silencing-induced Golgi fragmentation requires  
Rab6 activity .......................................................................................................43 
 
3.6  FCHo2-silenced cells show increased immature glycosylation structures but  
normal kinetics of Golgi to cell surface trafficking ...........................................45 
 




4.1  FCHo2 silencing fragments mitochondria ..........................................................61 
 
4.2  Co-silencing of Mon1a and tethers suppresses Golgi fragmentation .................63 
 














 I have to begin by thanking my family.  My sister, Brittany, and my parents, Ann 
and Barry, gave me all the support and strength I needed that allowed this work to be 
completed.  I am eternally grateful for them now and always. 
 I would like to thank my mentors, Jerry Kaplan and Diane Ward, who over the 
years have made me a better scientist.  I am grateful for all the time they spent shaping 
me into the young scientist I am today.  I am a better researcher because of them. 
 I would like to recognize my committee members, who always made time to 
discuss my science.  My research reaped the benefits of their guidance and expertise and I 























A unique and unifying characteristic of all eukaryotes is the evolution of 
intracellular compartmentalization.  The development of an elaborate endomembrane 
system has allowed for the separation of many biochemical processes, giving rise to 
sophisticated temporal and spatial regulation that is absent in prokaryotes (1-5).  A 
representative example of this is the separation that can be seen with protein synthesis in 
the endoplasmic reticulum and protein glycosylation within the Golgi apparatus.  The 
secretory and endocytic pathways of the endomembrane system are responsible for 
maintaining the size and shape of the cell.  The biosynthetic pathway is responsible for 
the synthesis and secretion of cytokines, hormones, antibodies, growth factors, receptors, 
ligands, and thousands of other cargoes.  Molecular machinery estimated at more than 
2000 proteins is required to insure fidelity and functionality of the endomembrane system 
(1,2,4,6).  Disruption of this machinery through genetic alteration or other means results 
in disease.  Diseases ranging from Chediak-Higashi to schizophrenia and cranio-
lenticulo-sutural dysplasia (CLSD) result from membrane traffic breakdown (7,8). 





regulated transport of proteins and lipids between these intracellular compartments has 
been a central question in cell biology. 
The anatomy of the endomembrane system was first described at the turn of the 
19th century when the Italian histologist Camillo Golgi identified an intracellular tubular 
structure using silver nitrate-based cytochemical staining to study the central nervous 
system (9,10).  The Golgi apparatus became the first endomembrane compartment 
identified.  Elie Metchnikoff, a contemporary of Golgi, demonstrated that individual cells 
possess machinery that allowed them to internalize extracellular material in a process that 
has since been termed endocytosis (9,11,12).  Biologists at this time were beginning to 
appreciate the nature of these intracellular membrane-bound organelles; however, it 
would be nearly another century before techniques were developed to define the enormity 
and complexity of the endomembrane system and regulatory machinery. 
In the mid-1900s seminal work by Palade, de Duve, and Novikoff using cell 
fractionation, enzymatic assays, and electron microscopy provided the critical insight that 
these membrane-bound intracellular compartments were sites of distinct biochemical 
functions (9).  Palade identified components of the mammalian endomembrane system by 
mapping the secretory pathway by pulse-chase autoradiographic tracing of zymogen 
enzyme in pancreatic tissue (9,13-15).  This work revealed directionality to the 
biosynthetic pathway.  Newly synthesized proteins in the ER are trafficked in vesicle 
intermediates to the Golgi apparatus to be matured and sorted.  Mature proteins leave the 
Golgi in secretory vesicles, ultimately reaching the plasma membrane (PM) for release of 
their content into the extracellular milieu.  This novel insight of ER to Golgi to PM 





RNA to protein.  Palade and colleagues framed the ultrastructural identity of the secretory 
and endocytic apparatuses; however, development of new techniques and technologies 
were necessary to uncover the molecular machinery required to regulate these complex 
intracellular pathways. 
Another critical observation stemming from the Palade laboratory was the 
fundamental principle that organelles communicate with their downstream counterpart 
through membrane-bound vesicle transport intermediates (16,17).  Further, for every 
forward (anterograde) trafficking step in the endomembrane system, a recycling 
(retrograde) trafficking event occurs that preserves the integrity of organelle composition 
and function (18-21).   Modern techniques including cell-free in vitro reconstitution 
assays, use of model organisms and genetic screens in conjunction with classical 
protocols of subcellular fractionation, and ultrastructural analysis began to define the 
complexity of the machinery required to regulate intracellular membrane trafficking.  In 
an elegant genetic screen using the budding yeast Saccharomyces cerevisiae, Randy 
Schekman and Peter Novick identified many of the molecular components required at the 
initial trafficking step of the secretory pathway, many of which have mammalian 
homologs (22-24). 
The focus of the work discussed in this thesis is the characterization of Mon1a, 
the mammalian homolog of yeast Mon1.  Mon1a was originally identified in a 








1.1 Identification of Mon1a: a membrane traffic regulator that affects 
iron metabolism 
Iron is an element essential in nearly all organisms because of its facile ability to 
gain and lose electrons, which is a process required in numerous biochemical processes 
(26,27).  For the same reason that iron can be beneficial, it also can be harmful at high 
concentrations.  Organisms must tightly regulate intracellular iron levels.  When this 
regulation breaks down, disease occurs.  Excessive tissue iron deposition is called 
hemochromatosis, which in humans has a highly variable clinical outcome. 
Hemochromatosis is a recessive disorder that arises due to mutations in a limited number 
of iron regulatory genes.  The variability in patient disease progression is likely the result 
of many genes modifying the outcome of iron overload (28).  In a QTL analysis, Mon1a 
was identified as a modifier of iron stores in different strains of mice (25). 
 Spleen iron content is largely supplied by macrophages that recycle iron from 
senescent red blood cells.  Spleen iron levels vary minimally between mice of the same 
sex and age but not between strains of mice.   Thus, spleen iron content was the trait 
followed in the QTL analysis.  C57BL and SWR mice were used for the QTL analysis as 
they had the lowest and highest spleen iron levels, respectively.  Ultimately, a single 
amino acid substitution was identified in an evolutionarily conserved residue (N374S) in 
the Mon1a allele unique to C57BL mice.  
Splenic iron levels are largely regulated by ferroportin, the only known 
mammalian iron exporter, and the mammalian Mon1a allele in C57BL macrophages 
results in significantly more ferroportin at the plasma membrane compared to SWR 
macrophages (25).  Excessive cell surface ferroportin expression is accompanied by a 





explanation for the differences observed in spleen iron content in these two mice strains.  
Depletion of Mon1a protein in bone marrow-derived macrophages using siRNA tested 
this hypothesis.  Decreased Mon1a protein led to a significant reduction in plasma 
membrane ferroportin and a concomitant increase in intracellular iron.  These results 
demonstrated that altering Mon1a levels affected cellular iron metabolism and accounted 
for the differences between C57BL and SWR mice spleen iron content. 
 Mon1a clearly affects the localization of ferroportin and ultimately iron 
metabolism but what was unclear was if Mon1a function was specific to iron regulation 
or was it more global.  Indeed, Mon1a silencing resulted in significant reduction in 
secretion of IL-12, IL-6, MIF, and other molecules, demonstrating that Mon1a regulated 
the movement of soluble and membrane-bound proteins through the secretory apparatus.  
This study suggested that the C57BL mice strain harbored an intrinsic “gain-of-function” 
Mon1a allele, which regulated the rate of traffic through the secretory apparatus.  
 
1.2 Identification of Mon1 in yeast 
 Selective cargo recruitment and faithful targeting of transport vesicles to 
accepting compartments preserves organelle identity and functionality by preventing 
homogenization of endomembrane compartments (2,5,29).  Studies in S. cerevisiae 
identified many components required for efficient bidirectional trafficking in the exo- and 
endocytic pathways (22-24,30).  Central to the endocytic pathway in yeast is the vacuole 
that houses many biochemical processes affecting cellular physiology, organelle 
turnover, and protein degradation.  The vacuole is subjected to constant fission and fusion 





become disrupted, vacuolar fidelity and maintenance of morphology break down.  
Analysis of a gene deletion library revealed Mon1 and another protein, Ccz1, are required 
for proper trafficking to the vacuole as well as maintaining vacuole architecture (30,31). 
 Material enters the vacuole through a number of regulated pathways including 
autophagy, the multivesicular body (MVB) pathway, and the secretory pathway.  Certain 
hydrolases, including soluble aminopeptidase I (Ape1), that reside in the vacuole, traffic 
through the cytoplasm to vacuole targeting (Cvt) pathway as immature peptides and are 
then cleaved into their mature form in the acidic environment of the vacuole.  
Importantly, processes and machinery required in the Cvt pathway overlap with those of 
autophagy and other trafficking events (30).  To gain insight into these processes, a yeast 
gene deletion library was screened to identify mutants with defects in Ape1 maturation.  
Two gene products, Mon1 and Ccz1, which had previously not been implicated in these 
pathways, were found to be required for Cvt/autophagy-based vacuolar import (30,31). 
 Genetic, biochemical, and morphological analysis revealed a role for Mon1 and 
Ccz1 in fusion at the vacuole.  Mon1 forms a stable complex with Ccz1 and the complex 
is recruited to the vacuole where it peripherally associates with the membrane.  Deletion 
of Mon1 or Ccz1 disrupts membrane localization of the other protein and subsequently its 
function.  In the absence of Mon1 or Ccz1, all membrane traffic that terminates at the 
vacuole (e.g. autophagy, Cvt, MVB, CPY pathways) is defective at the step of vacuolar 
fusion.  Yeast strains lacking Mon1 or Ccz1 present with fragmented vacuoles, missorted 
vacuolar hydrolases (e.g. CPY), and are sensitive to high zinc concentrations (30-33).  
Mon1 and Ccz1 are required for homotypic vacuole fusion and function as a component 





deleted in yeast.  Further work suggested that the Mon1-Ccz1 complex acts as a guanine 
nucleotide exchange factor (GEF), activating the late endosomal GTPase Ypt7, which is 
required for docking and fusion. 
 
1.3 The role of SAND-1/Mon1a/b in the endocytic pathway 
 Mon1 is evolutionarily conserved and is found in all organisms from yeast to 
humans.  There is only a single copy of Mon1 in yeast and C. elegans, yet there are two 
vertebrate homologues, Mon1a and Mon1b.  Mon1 was originally characterized in yeast 
and its role was defined in the endocytic pathway.  Understanding the function of Mon1 
in the endocytic pathway of higher eukaryotes was the focus of recent studies, which 
revealed a requirement for Mon1, specifically in the maturation of the endosomal 
compartment (34-36). 
 Genetic and cell biological studies in C. elegans were done to analyze the role of 
the nematode homolog of Mon1, SAND-1 (36,37).  or552 is a temperature-sensitive 
mutation of SAND-1.  or552 is embryonic-lethal because it harbors a lesion in SAND-1, 
which is named after an evolutionarily conserved domain (the SAND domain) of 
unknown function.  These or552 mutant worms presented with an accumulation of 
granules in oocytes and coelomocytes.  The granules originated from the endosomal 
pathway and were of both early and late endosomal origins.  The study demonstrated that 
SAND-1 was a cytosolic protein peripherally associated with membranes of the early and 
late endocytic compartments.  Further, SAND-1 was required for the membrane 
localization of the small Rab family GTPase Rab7.  Rab7 function is required for the 





transition at early to late endosomes, SAND-1 is not required at lysosomes despite its role 
in yeast.  The authors claimed that Mon1 is functionally conserved from yeast to worms 
because SAND-1 is able to partially rescue Δmon1 strains, despite functioning in distinct 
cellular environments. 
 Further studies in C. elegans showed that SAND-1 was required for the lysosomal 
degradation of engulfed apoptotic cells.  Use of a sand-1 (ok1963) deletion mutant or 
RNAi against sand-1 revealed an increase in the number of refractile bodies, condensed 
apoptotic cells found in the gonads of these worms.  Refractile bodies stained brightly 
with acidic markers acridine orange and LysoTracker in the sand-1 mutant, suggesting 
that apoptotic cells were internalized and acidified without impairment yet were defective 
later in the process of phagosomal maturation.  The investigators posited that Mon1a 
function is evolutionarily conserved because clearance of apoptotic cells was rescued to 
wild type levels when mammalian Mon1a was expressed in the sand-1 mutants.  After 
cell corpse internalization, phagosomes mature from a Rab5+ to a Rab7+ compartment 
and in the absence of SAND-1 there was an increase in Rab5+ phagosomes with a 
concomitant decrease of Rab7+ phagosomes.  Mechanistically, SAND-1/Mon1 affects 
Rab5 activation and downstream recruitment of Rab7, transitioning phagosomes to a 
more mature phenotype by removing the negative regulator of Rab7, a GDP dissociation 
inhibitor (GDI) (34). 
 Studies in mammalian cells showed that the mammalian Mon1 homologs also 
played a role in endosomal maturation.  HeLa cells treated with siRNA oligos specifically 
targeted to Mon1a and Mon1b demonstrated an increase in the size of Rab5+ endosomes, 





Mon1b alone (35).  Rab5 is activated through a GEF Rabex5, which was displaced 
through the overexpression of both Mon1a/b.  Notably, Mon1b, but not Mon1a, 
interacted with the HOPS complex, which is known to recruit and activate Rab7 through 
GEF activity.  This work demonstrated that SAND-1/Mon1b functions in the conversion 
of early (Rab5+) to late (Rab7+) endosomes by displacing Rabex5, the activator of Rab5, 
thus disrupting a positive feedback loop, recruitment, and activation of Rab7, likely 
through an interaction with the Rab7 GEF, the HOPS complex (35). 
 These studies demonstrated a role for Mon1 in the endocytic pathway, specifically 
in the maturation of early- to late- endosomes.  Mon1 is evolutionarily conserved but the 
two vertebrate homologues (Mon1a and b) share less than 50% identity.  Much of the 
work on Mon1 function in the endocytic pathway of mammalian cells focused on the role 
of Mon1b and much less on Mon1a (34,35).  Also, these studies ignored the fact that 
mammalian Mon1a was originally identified as a regulator of membrane trafficking in the 
secretory pathway.  None of the work published on Mon1 excludes it from functioning in 
the biosynthetic pathway and therefore, the aim of this thesis is to understand Mon1a 
activity, specifically in the mammalian secretory pathway.  A short overview of the steps 
required for trafficking in the early secretory pathway are discussed below. 
 
1.4 ER-derived vesicle formation 
It is estimated that one third of the proteome is synthesized and packaged for 
transport at the ER, the initial step of membrane trafficking in the secretory pathway 
(1,5,29).  Newly synthesized proteins are recruited and concentrated into ER-derived 





recruitment and vesicle formation at ERES occurs via the sequential recruitment of the 
cytosolic proteins collectively known as the coat protein complex II (COPII).  COPII 
proteins were originally identified in the Schekman S. cerevisiae genetic screen and are 
highly conserved in all eukaryotes (22-24). 
COPII coat formation is initiated by the activation of the small GTPase Sar1 
through a nucleotide exchange factor, Sec12, which activates Sar1.  Activated Sar1 is 
recruited to the ERES membrane via insertion of an amphipathic α-helix, which creates 
membrane curvature while recruiting the heterodimeric Sec23-24 complex (“inner coat”) 
that forms a concave, basic surface that is thought to stabilize and/or induce membrane 
curvature.  The “outer coat” is subsequently recruited and is the product of another 
heterodimer complex, Sec13-31, which is believed to stabilize curvature and coat 
assembly as well as aid in vesicle scission, though the precise mechanism remains 
unclear (38,39).  These five coat proteins have been demonstrated to be the minimal unit 
sufficient for vesicle formation using in vitro liposome-based assays; however, how 
vesicles are released and trafficked downstream to the intermediate compartment in vivo 
is still not fully understood. 
Microtubules (MT) and the microtubule-based molecular motor Dynein are 
required for efficient ER to Golgi transport (40).  Exactly how they function at a 
mechanistic level in vesicle formation and trafficking at the ER remains an open 
question.  Several studies demonstrate that cargo is trafficked to the ER-Golgi 
intermediate compartment (ERGIC) in the presence of MT depolymerizing agents, 
suggesting that this initial transport step is MT-independent.  Conversely, other studies 





dynactin motor, Bicaudal-D (BICD1), interacts with the COPII inner coat protein Sec23 
(20).  Inhibiting this interaction delays vesicle trafficking to the Golgi apparatus, 
demonstrating that despite the significant strides to understanding vesicle trafficking at 
the early anterograde pathway, much remains to be elucidated.  How Mon1a function is 
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 Mon1 is an evolutionarily conserved protein involved in membrane trafficking (1-
3).  Yeast Mon1 is a cytosolic protein recruited to the vacuole and is required for all 
fusion events involving the vacuole, including autophagy, cytoplasm to vacuole targeting 
(Cvt), and multivesicular body (MVB) pathways (4-6).  In the nematode Caenorhabditis 
elegans, Mon1 is required for Rab7 activity, which is necessary for the transition from 
early to late endosomes (7).  Mammals have two homologues of Mon1, Mon1a and 
Mon1b, which share less than 50% similarity at the amino acid level.   In C. elegans, 
these Mon1 homologues may also be involved in endosome maturation.  At endosomes, 
Mon1 is thought to displace the activator of Rab5, Rabex5, allowing for the recruitment 
of Rab7 to endosomal surfaces, thus permitting maturation to a late endosomal 
compartment (3). Reduction in Mon1a or Mon1b levels alone had no reported effect on 
endosomal morphology or maturation.  However, reductions in both Mon1a and Mon1b 
showed an increase in the size of the Rab5 compartment and a concomitant decrease in 




Mon1a had been identified as a modifier gene of splenic iron content with mice 
having different levels of splenic iron depending on the allele status of Mon1.  The Mon1 
allele in C57BL mice has a missense mutation, which led to higher cell surface levels of 
the iron exporter ferroportin and consequently a lower cellular iron content.  Silencing 
studies in cultured cells demonstrated that RNAi-mediated depletion of Mon1a resulted 
in decreased expression of plasma membrane proteins and decreased protein secretion but 
had no discernable effect on endocytosis (8).  Further studies demonstrated that Mon1a 
played a role in ER to Golgi traffic, as a reduction in Mon1a decreased ER vesicle 
formation.  Protein interaction studies found that Mon1a associated with the microtuble 
(MT)-based motor Dynein and RNAi-mediated loss of either protein impaired ER to 
Golgi traffic (1).   
Evidence that Mon1a acts at the ER, however, does not preclude it from having 
roles in other trafficking steps.  Notably, reductions in Mon1a showed a mild 
morphological effect on the Golgi apparatus (1).  Here we present data showing that 
severely reduced levels of Mon1a has a significant effect on Golgi morphology.  Further, 
we show that Mon1a interacts with FCHo2, a protein involved in membrane bending and 
curvature stabilization at the plasma membrane.  Our data suggest that FCHo2 is required 
for Golgi ribbon formation following mitosis. 
 
 
3.2 Experimental Procedures 
3.2.1 Mammalian cells and constructs.  NIH3T3, Hela, and GalNAc-T2-GFP 
expressing Hela cells were maintained in DMEM with 10% FBS plus or minus 0.4 g/L 




from Dr. Brian Storrie (University of Arkansas).  VSVGtsGFP were a generous gift from 
Dr. Jennifer Lippincott-Schwartz (National Institutes of Health).  Mouse Mon1a was 
cloned into pCMV-Tag2BFLAG (Stratagene, La Jolla, CA) or pEGFPC1 (Clontech, 
Mountain View, CA).  All constructs were sequence verified prior to use.   
 3.2.2 Transfections and Western analysis.  HeLa, NIH3T3, or GalNAc-T2-GFP 
cells were plated onto tissue culture plates and allowed to grow for 24 to 48 h to 50-80% 
confluence.  The cells were transfected with various constructs using Amaxa nucleofector 
technology (Lonza, Walkersville, MD) according to the manufacturer’s directions.  
Protein expression was determined by solubilizing 2–4 x 106 cells in lysis buffer plus 2X 
protease inhibitor cocktail (Roche Applied Science, Boulder, CO).  Samples were 
analyzed by SDS-PAGE and Western analysis was performed using either mouse anti-
FLAG antibody (1:1000; Sigma-Aldrich, St. Louis, MO); rabbit anti-GFP (1:5000, 
ab6556; Abcam); mouse anti-tubulin (1:1000; GeneTex, San Antonio, TX) or mouse anti-
Dyn-IC (1:2000, MMS-400R Covance, Princeton, NJ) followed by either peroxidase-
conjugated goat anti-mouse immunoglobulin IgG (1:10,000; Jackson ImmunoResearch 
Laboratories, West Grove, PA) or peroxidase-conjugated goat anti-rabbit IgG (1:10,000; 
Jackson ImmunoResearch Labs, West Grove, PA).  Antibodies to Mon1a and FCHo2 
were generated as described (1).  Rabbit anti-Mon1a and FCHo2 were used at a 
concentration of 1:100-500 followed by peroxidase conjugated goat anti-rabbit IgG 
(1:10,000) (Jackson ImmunoResearch Labs, West Grove, PA).  The blots were developed 
using Western Lightning reagent (PerkinElmer Life Sciences, Waltham, MA).  Tubulin 
was used as a loading control.  All experiments were performed a minimum of three 




3.2.3 Size exclusion chromatography.  Cells expressing FLAG-tagged Mon1a 
were lysed in TBS pH 7.4 containing 0.1% Triton X-100 at 0°C for 45 min.  The lysate 
was spun down at 14,000 RPM for 10 min and filtered through a 0.2-micron filter before 
running over a FPLC HiLoad 16/20 Superdex 200 prep grade column (Amersham 
Biosciences, Pittsburg, PA) at 0.5 mL/minute collecting 1 mL fractions.  The analysis of 
FLAG-Mon1a presence in the FPLC fractions was resolved by SDS-PAGE and Western 
blot analysis. 
 3.2.4 Yeast two-hybrid (Y2H) and co-immunoprecipitation protein interaction 
studies.  A Mon1a protein fragment containing the first 200 residues was used as a bait to 
screen a library of potential interacting partners in budding yeast as described previously 
(9).  Cells were transfected with pFLAG-Mon1a or GFP-Mon1a, solubilized in lysis 
buffer, incubated 0ºC, 30 min, centrifuged at 10,000 x g, 10 min, immunoprecipitated 
using mouse anti-FLAG antibody (Sigma, St. Louis, MO) or rabbit anti-GFP (GeneTex, 
San Antonio, TX) and protein A/G-plus agarose (Santa Cruz Biotech, Santa Cruz, CA).  
Proteins in the immunoprecipitate were identified using Western blot analysis as 
described above (1). 
3.2.5 Treatment with siRNA oligonucleotide pools.  Cells were treated with 
nonspecific (NS), Mon1a (5’-UTR), Mon1a (ORF), FCHo2, Rab6a, or dynein heavy 
chain1-specific oligonucleotides (Dharmacon SiGenome SiRNA SMARTpool; 
Dharmacon RNA Technologies, Layfette, CO and University of Utah Sequencing Core; 
Salt Lake City, UT) using Oligofectamine Reagent (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s instructions as previously described (1).  Briefly, 175,000 cells 




CA) for 6 h at 37°C before serum-replete medium was added for overnight growth.  Cells 
were allowed to grow in DMEM with 10% FBS for 72 h before analyses were completed. 
 3.2.6 Brefeldin A treatment.  Cells plated on glass coverslips were incubated with 
5 µg/mL Brefeldin A (BFA) (Epicentre Biotechnologies, Madison, WI) for 30 min, 
washed three times, and placed in growth media for recovery.  BFA recovery was 
visualized using an Olympus BX51 upright microscope with a 100X 1.4NA objective and 
Pictureframer software (Olympus, Melville, NY). 
 3.2.7 Epifluorescence and electron microscopy.  Confocal images were captured 
on a Nikon A1R with the 488nm laser line and a 60x PLANAPO OIL immersion 
objective.  Image analysis was performed using Volocity software as previously 
described (1).  For electron microscopy (EM), cells were fixed in 2.5% 
glutaraldehyde/1% paraformaldehyde and transmission EM images capture at the 
University of Utah EM Core as previously described (1). 
3.2.8 FRAP analysis.  Cell transfected with siRNAs for nonspecific or FCHo2 
were analyzed for lateral diffusions and membrane fusion of Golgi GalNAc-T2-GFP by 
photobleaching and recovery.  FRAP was performed using a Nikon A1R with the 488nm 
laser line and a 60X PLANAPO OIL immersion objective. Regions of interest were 
selected for photobleaching and after three initial frames, 100% laser power was applied 
to these regions for 2 seconds, followed by time-lapse imaging of the recovery at one 







3.3.1 Mon1a interacts with the F-BAR protein FCHo2.  We demonstrated that 
Mon1a is required for efficient anterograde trafficking in the secretory pathway due to its 
interaction with the microtubule-based molecular motor Dynein (1).  A yeast two-hybrid 
(Y2H) screen was performed to identify interacting partners of Mon1a to give us insight 
into Mon1a function.  A protein fragment containing the first 200 residues of Mon1a, 
used as bait, was found to interact with five different proteins (Table 3.1).   We focused 
on one protein, the endocytosis effector FCHo2, as it was found from three different 
mammalian libraries and is known to function in membrane trafficking.  FCHo2 is a F-
BAR domain-containing protein that functions at the cell-surface as part of the machinery 
 
Table 3.1 Yeast two-hybrid (Y2H) analysis of Mon1a binding partners 
Bait Amino acids Prey a.a. cords. Library 
Mon1a (Hs) 1-200 FCHo2 13-177 Macrophage 
Mon1a (Hs) 1-200 FCHo2 7-106 Spleen 
Mon1a (Hs) 1-200 FCHo2 14-150 Brain 
Mon1a (Hs) 1-250 DPY30(99) 36-100 Macrophage 
Mon1a (Hs) 1-200 FYN(537) 97-219 Brain 
Mon1a (Hs) 1-200 LYN(582) 78-276 Spleen 
Mon1a (Hs) 1-200 TXN -18-106 Spleen 
A yeast two-hybrid screen was performed using human Mon1a as bait.  The first 200 
amino acids of Mon1a was shown to interact with the clathrin-dependent endocytosis 
effector FCHo2.  This interaction was seen in multiple independent libraries constructed 
from macrophages, spleen, and brain tissues.  Mon1a was also shown to physically 
associate with Dpy30-like protein (99), a protein thought to be involved in the 
methylation of histones, tyrosine-protein kinases Fyn and Lyn, thought to be involved in 
several biological processes including cell growth and activation, respectively, as well as 





necessary for clathrin-dependent endocytosis (10). The yeast two-hybrid result was 
corroborated by size exclusion chromatography and coimmunoprecipitation.  Lysates 
from cells over-expressing functional FLAG-tagged Mon1a protein were passed over a 
size-exclusion column.  Mon1a is predicted to be a 62 kDa protein, yet the majority of 
Mon1a migrated in two distinct sets of fractions that were about 150 kDa and in the void 
volume, which contains molecules greater than 330 kDa.  This result suggests that Mon1a 
associates with other proteins as a higher molecular weight complex (Figure 3.1A).  
Mon1a was found in fractions the size consistent for Mon1a interacting with itself as a 
dimer (~150 kDa).  To address the possibility of Mon1a dimerization, FLAG- and GFP-
tagged Mon1a were co-expressed in NIH3T3 cells, GFP-Mon1a was 
immunoprecipitated, and the presence of FLAG-tagged Mon1a assessed by Western blot.  
Mon1a dimerization was confirmed, as GFP-Mon1a was able to pull down FLAG-Mon1a 
(Figure 3.1B).  This interaction was specific as free GFP was unable to co-
immunoprecipitate FLAG-Mon1a.  To address whether Mon1a interacts with FCHo2, 
FLAG-Mon1a was immunoprecipitated from the high molecular weight FPLC fraction 
and the immunoprecipitate examined for the presence of FCHo2.  FLAG-Mon1a 
interacted with endogenous FCHo2 as well as Dynein, a protein known to interact with 
Mon1a (Figure 3.1C) (1).  FLAG-tagged Mon1a migrated in a void volume fraction 
consistent with a higher-order protein complex (Figure 3.1A).  These results support an 
association between Mon1a and FCHo2 but do not distinguish if this interaction is direct 
or indirect.  Our previous studies demonstrated that endocytosis was seemingly 
undisrupted in Mon1a deficient cells; however, a role for FCHo2 in the secretory 





Figure 3.1 Mon1a dimerizes and associates with the endocytic F-BAR domain protein 
FCHo2  A.  NIH3T3 cells were transfected by FLAG-Mon1a before lysing in the 
presence of 0.1% Triton X-100.  Whole cell lysates were passed through a filter before 
injecting over a FPLC size-exclusion column.  Fractions were resolved by SDS-PAGE 
and Western analysis using mouse anti-FLAG antibodies.  B. pEGFP, GFP-, and FLAG-
Mon1a constructs were co-expressed in NIH3T3 cells and lysed.  Lysates were incubated 
with a GFP antibody and A/G-plus sephrose beads and samples were analyzed by SDS-
PAGE and Western blot analysis for co-immunoprecipitation.  C.  Cells expressing 
FLAG-Mon1a were lysed and incubated with FLAG antibody and A/G-plus beads to 
immunoprecipitate FLAG-Mon1a.  SDS-PAGE and Western analysis were done to 
confirm protein interactions. 
 
 
3.3.2 FCHo2 is required for Golgi maintenance but not anterograde trafficking.  
The Golgi complex resides at the center of the biosynthetic pathway, constantly receiving 
an input of newly synthesized proteins and lipids. We previously demonstrated that 
Mon1a depletion by siRNA alters the structure of the Golgi while leaving cisternae intact 
(1).  To determine if FCHo2 has a role in the secretory pathway, we used siRNA to 




resident Golgi enzyme that labels the entirety of the Golgi apparatus (11,12).  We 
observed organized perinuclear Golgi stacks with intact cisternae in cells transfected with 
nonspecific targeting siRNAs.  In contrast, cells transfected with human FCHo2-specific 
siRNAs showed fragmented Golgi stacks.  Golgi ribbons were disrupted but remained 
centrally clustered (Figure 3.2A).  Notably, we assessed Golgi architecture in FCHo1-
silenced cells, the FCHo2 homolog that also functions in clatherin-mediated endocytosis; 
however, Golgi remained intact so we focused our studies on FCHo2. 
 Confocal imaging was used to characterize further the breakdown of Golgi 
complex in FCHo2-depleted cells.  Confocal images of cells transfected with nonspecific 
control siRNA showed tightly organized Golgi stacks at the perinucleus.  In contrast, 
FCHo2-silenced cells presented fragmented Golgi, which was quantified using Volocity 
software to measure the GalNAc-T2-GFP signal in three-dimensional space on a cell-by-
cell basis (1).  The number of Golgi elements (GalNAc-T2-GFP+) was dramatically 
increased in FCHo2 silenced cells compared to nonspecifically siRNA transfected control 
cells (Figure 3.2B).  Measurements of FCHo2-depleted cells demonstrated a bimodal 
distribution of surface area to volume for Golgi fragments, with a significantly increased 
number of Golgi fragments as compared to control cells, which showed intact uniformly 
sized Golgi (Figure 3.2B).  Consistent with the confocal data and Volocity 
measurements, electron micrographs of cells with reduced levels of FCHo2 also showed 
severely fragmented Golgi phenotype.  Cells showing less fragmented, individual mini-
stacks lacking ribbon structures were also present.  Control cells consistently displayed 






Figure 3.2 FCHo2 is required for maintenance of Golgi architecture  A.  HeLa cells 
expressing the Golgi protein GalNAc-T2-GFP were treated with siRNAs specific to 
FCHo2 or nonspecific control siRNAs for 72hrs.  Western analysis was done to confirm 
efficient reduction of FCHo2.  Golgi morphology was analyzed using live cell 
epifluorescence imaging of GalNAc-T2-GFP signal with a confocal microscope.  B. Cells 
silenced as in (A) were imaged using confocal microscopy and images, specifically the 
Golgi channel, were quantified using Volocity software as described previously (1).  Data 
are expressed as Golgi elements/cell or average Golgi surface area/volume expressed as 
voxels. C.  Cells silenced as in (A) for nonspecific control or FCHo2-specific siRNAs 
were processed for electron micrograph analysis at 72hrs RNAi-treatment.  






 We have shown that FCHo2 physically interacts with Mon1a, a protein that is 
known to function in anterograde trafficking within the secretory pathway.   A role for  
FCHo2 in the secretory pathway, however, has yet to be described. Golgi fragmentation 
in FCHo2 silenced cells could result from a defect in the anterograde pathway (12,13).  
To address this question, HeLa cells expressing GalNAc-T2-GFP were transfected with 
FCHo2 siRNAs for 72 hours prior to treatment with the fungal metabolite Brefeldin A 
(BFA).  BFA causes a dramatic redistribution of Golgi membrane to the ER (14).  
Removal of BFA by washing allows the Golgi to reassemble.  Cells transfected with 
nonspecific control siRNA recovered Golgi stacks 2 h after BFA was removed (Figure 
3.3).  Since FCHo2-silenced cells recovered their fragmented Golgi with the same 
kinetics as control cells (Figure 3.3), we conclude that the disorganized architecture of 




Figure 3.3 FCHo2 is not required for ER-Golgi transport  HeLa cells stably expressing 
GalNAc-T2-GFP treated with siRNAs as described in Figure 2.  Silenced cells were then 
incubated with BFA (5 μg/mL) for 30 min at 37°C before stringent washing.  Movement 





3.3.3 siRNA targeting Mon1a (5’-UTR) results in Golgi fragmentation.  One 
limitation of protein depletion through siRNA targeting is that RNAi can decrease mRNA 
and protein levels but cannot completely eliminate the expression of a target protein (15).  
RNAi oligos vary dramatically in inhibitory efficacy and the testing of a pool of oligos to 
a particular gene target is therefore commonly used to overcome this concern.  Both 
Dynein and FCHo2 interact with Mon1a and fragment the Golgi apparatus when reduced 
by RNAi, yet Mon1a silencing only disorganizes the Golgi while leaving the cisternae 
intact (1).  One hypothesis for this less severe Golgi phenotype is that Mon1a is required 
in both anterograde and retrograde trafficking at the ER-Golgi interface, which would 
likely preserve the architecture of the Golgi.  Another possibility is that the residual 
Mon1a protein remaining after RNAi treatment is sufficient for Golgi complex 
maintenance.  To test this latter possibility, RNAi oligos were designed to target either 
the open reading frame (ORF) or the 5’-untranslated region (5’-UTR) of Mon1a to test 
for differences in the efficiency of silencing between the two oligos.  HeLa cells 
expressing GalNAc-T2-GFP were treated with each siRNA for 72 hours and Golgi 
morphology was assayed by epifluorescence microscopy.  RNAi oligos specific to a 
sequence in the ORF of Mon1a led to the same Golgi phenotype as previously published, 
the Golgi was disorganized yet remained intact.  Surprisingly, cells treated with oligos 
targeting the 5’-UTR of Mon1a led to fragmented Golgi stacks that were similar to that 
seen in FCHo2 silenced cells (Figure 3.4A). Rescue experiments were performed to 
confirm that this phenotype was specific to Mon1a protein depletion.  Mon1a (5’-UTR) 
silenced cells were transfected with a FLAG-tagged mouse allele of Mon1a, which is 




Golgi trafficking that require Mon1a function.  Compared to an empty vector control, 
Mon1a (5’-UTR) silenced cells expressing FLAG-Mon1a recovered both Golgi 
architecture and ER-Golgi trafficking comparable to nonspecifically silenced control 
cells, demonstrating that this new Golgi phenotype is specific to Mon1a protein 
suppression (Figure 3.4B).  Electron micrograph analysis demonstrated that Mon1a 
protein suppression via RNAi resulted in a Golgi fragmentation strikingly similar to those 
seen in FCHo2 silenced cells (Figure 3.4C). 
3.3.4 Co-depletion of Rab6 and FCHo2 or Mon1a (5’-UTR) suppresses 
silencing-induced Golgi fragmentation.  The Golgi GTPase Rab6 and ER tether ZW10 
function in vesicle fission and fusion, respectively, are required for the fidelity of 
membrane traffic and maintenance of Golgi morphology (12).  Studies demonstrated that 
RNAi-dependent knockdown of the retrograde tether ZW10/RINT-1 resulted in a central 
clustering of Golgi fragments (12).  This phenotype is strikingly similar to the Mon1a 
(5’-UTR) and FCHo2 knockdown-induced Golgi phenotypes.  Rab6 is an evolutionarily 
conserved GTPase known to facilitate trafficking from the Golgi to the cell surface 
(anterograde), intra-Golgi transport mediated by the retrograde tether complex COG, and 
trafficking from the Golgi to the ER (retrograde) through a physical interaction with 
Dynein (12,16,17).  Rab6 functions epistatic of ZW10, as co-silencing resulted in a Rab6 
phenotype with intact Golgi architecture (12).  We hypothesize that the Golgi 
fragmentation we observe in Mon1a (5’-UTR) and FCHo2 silenced cells requires the 
trafficking activity of Rab6.  To test this possibility, GalNAc-T2-GFP expressing HeLa 
cells were treated with siRNA oligonucleotides, alone or in combination, specific to 





















Figure 3.4 siRNA targeting 5’-UTR of Mon1a fragments the Golgi apparatus  GalNAc-
T2-GFP expressing HeLa cells were transfected with siRNA specific to either the ORF or 
5’-UTR of the Mon1a gene. A.  Epifluorescence Golgi morphological analysis of Mon1a 
(ORF) versus (5’-UTR) silenced cells as compared to nonspecific control cells. B.  
Mon1a-silenced cells were transfected with FLAG-Mon1a or an empty vector control and 
Golgi morphology and ER-Golgi trafficking using a BFA recovery assessed by 
microscopy. C.  siRNA transfected cells were fixed at 72 hours of silencing and 









Golgi cisternae while Mon1a (5’-UTR) and FCHo2-silenced cells possessed fragmented 
Golgi elements as previously demonstrated (Figure 3.5A).  Co-silencing of Rab6 and 
FCHo2 or Mon1a (5’-UTR) preserved the morphology of the Golgi stacks, resulting in a 
Rab6 silencing phenotype as opposed to a fragmented morphology.  The percentage of 
cells showing Golgi fragmentation was quantified (Figure 3.5B).  That depletion of 
Rab6a suppresses the effects of Mon1a and FCHo2 silencing suggests that Golgi 
fragmentation requires the function of the Golgi GTPase Rab6. 
3.3.5 FCHo2 depletion does not affect vesicle traffic through the secretory 
pathway.  Studies have shown that Golgi fragmentation does not necessarily impair 
secretion (23,26).  Previously, we determined that reductions in Mon1a affected ER to 
Golgi and Golgi to plasma membrane (PM) trafficking (1). To determine if reductions in 
FCHo2 affect ER to Golgi and Golgi to PM trafficking, we took advantage of a 
temperature-sensitive allele of VSVGtsGFP that concentrates and restricts its localization 
to the ER at the restrictive temperature (39°C).  Shifting cells to 32ºC allows cells to 
traffic VSVGtsGFP from ER to Golgi.  Trafficking from ER to Golgi was unimpaired in 
FCHo2 silenced cells although the Golgi structures remained fragmented (Figure 3.6A).  
An intrinsic trait of all mammalian cells is that membrane traffic is temperature-sensitive.  
Incubation of cells at 20°C allows trafficking from the ER to the Golgi but no further.  
Silenced cells were transfected with VSVGtsGFP and incubated overnight at 39°C to 
restrict VSVGtsGFP to the ER.  The analysis of FCHo2 function in Golgi-PM transport 
was done by allowing VSVGtsGFP to accumulate at the Golgi at 20°C.  In control and 
FCHo2-depleted cells, the movement of VSVGtsGFP out of the Golgi to the cell surface 




Figure 3.5 Mon1a (5’-UTR) and FCHo2 silencing-induced Golgi fragmentation requires 
Rab6 activity  A.  HeLa cells expressing GalNAc-T2-GFP were silenced with Mon1a (5’-
UTR), FCHo2 or Rab6 alone or in combination for 72 hours.  Epistasis was established 
by scoring Golgi morphology using live cell epifluorescence microscopy. B.  
Quantification of four independent epistasis experiments showing percent Golgi 




suggest that FCHo2 is not required in vesicle trafficking through the secretory pathway. 
 It is known that glycosylation of proteins can be impaired when properly 
organized Golgi architecture is broken down.  Carbohydrate processing requires the 
sequential activity of a number of enzymes that span the entirety of the Golgi stack 
(26,27).  N-acetyl-D-glucosamine is a rare, immature carbohydrate structure that is 
typically seen on cells where the sequential activity of glycosylation enzymes is disrupted 
through Golgi fragmentation (26).  To determine if FCHo2 or Mon1a depletion disrupts 
proper glycosylation of proteins localized at the plasma membrane, silenced cells were 
placed at 0ºC and incubated with an Alexa594-conjugated lectin (GS-II) that binds the 
immature glycosylation mark N-acetyl-D-glucosamine of cell surface proteins.  FCHo2 
silenced cells had significantly increased GS-II binding at the cell surface while control 
cells had almost no GS-II fluorescence (Figure 3.6B).  These data demonstrate that 
FCHo2 reduction disrupts Golgi architecture impairing proper glycosylation yet 
trafficking through the Golgi to the cell surface is uninhibited. 
3.3.6 Golgi fragmentation in FCHo2-depleted cells is cell cycle-dependent.  The 
mammalian Golgi apparatus consists of individual stacks of Golgi cisternae, termed 
“mini-stacks”.  Golgi membrane laterally link individual stacks through membrane 
tubules, creating Golgi “ribbons” (18-20).  Golgi material must be partitioned between 
daughter cells during mitosis, which is facilitated through the systematic breakdown of 
Golgi ribbons to individual stacks and ultimately into vesicles.  After cell division, the 
vesiculated Golgi coalesces and the organelle is reassembled independently in each 
daughter cell (19,20).  Reductions in FCHo2 protein cause Golgi to fragment, 





Figure 3.6 FCHo2-silenced cells show normal kinetics of Golgi to cell surface trafficking 
but increased immature glycosylation structures   A.  HeLa cells transfected with 
nonspecific or FCHo2-specific siRNA for 48 h and then cells were transfected with 
VSVGtsGFP and grown overnight at 39.5°C.  Cells were shifted to 20°C for 2 h to allow 
VSVGtsGFP capture in the Golgi apparatus.  Cells were then shifted to the permissive 
temperature (32ºC) and images captured at 30 and 60 min. B.  Cells silenced as in (A) for 
72 h were incubated at 4ºC with the cell impermeable Alexa594-conjugate GS-II lectin.  
Cells were extensively washed and epifluorescence images captured.  Representative 







could give rise to this phenotype.  First, mini-stack fragments in FCHo2-silenced cells 
may result from ribbon breakdown.  Golgi ribbon maintenance may require membrane 
stabilization, which is a known activity of F-BAR domain family members.  If FCHo2 is 
required for ribbon stability, then reducing FCHo2 levels should be sufficient to induce 
Golgi fragmentation.  Alternatively, FCHo2 may act after mitosis when Golgi 
reformation occurs by actively tubulating Golgi membranes to link individual stacks and 
thus creating Golgi ribbons.  F-BAR proteins like FCHo2 have been observed to cause 
massive membrane tubulation when highly expressed in cell culture (21,22), an activity 
presumably required in Golgi ribbon formation.  RNAi and cell cycle arrest were utilized 
to address if FCHo2 or Mon1a activity were required in Golgi ribbon stability versus 
ribbon formation.  Suppression of Golgi fragmentation by arresting the cell cycle in 
silenced cells would strongly suggest that FCHo2/Mon1a activity is required after mitosis 
in Golgi ribbon formation.  To test this hypothesis, FCHo2 and Mon1a (5’-UTR) were 
knocked down using siRNA in cell cycle-arrested, GalNAc-expressing HeLa cells.  
Continued incubation in thymidine blocks cells at the G1/S phase, arresting the cell cycle 
before mitosis preventing Golgi disassembly.  Control cells after 72 h of nonspecific 
silencing possessed tight, organized Golgi stacks in the presence or absence of thymidine 
(Figure 3.7A).  As a control, we also silenced Dynein, which causes Golgi fragmentation 
into vesicles that presumably is not cell cycle-dependent.  The presence or absence of 
thymidine did not alter the level of Golgi fragmentation observed in Dynein depleted 
cells.  In contrast, the presence of thymidine in FCHo2-silenced cells in showed intact, 
organized Golgi stacks, whereas in the absence of thymidine treatment, the Golgi stacks 




phenotype is cell cycle-dependent.  Golgi morphology was scored and quantified over 
several experiments and cell cycle arrest significantly suppressed FCHo2 silencing-
induced Golgi fragmentation (Figure 3.7B).  Mon1a (5’-UTR) treated cells showed a 
modest but not significant suppression of Golgi fragmentation in thymidine treated cells, 
suggesting that this phenotype is not cell cycle-dependent.   
 These cell cycle data strongly suggests that FCHo2 is required for the reassembly 
of the Golgi apparatus at the level of Golgi ribbon formation, which requires the fusion of 
Golgi membranes (23).  The Golgi complex in mammalian cells is a dynamic structure 
where contents within cisternae are laterally mixed as the Golgi reassembles and ribbons 
form following mitotic events (19).  The architecture of Golgi stacks is disrupted in cells 
with markedly reduced levels FCHo2 or Mon1a, but it is not known if there is 
communication between these fragmented Golgi elements through membrane fission and 
fusion events.  We utilized fluorescence recovery after photobleaching (FRAP) (23-26) to 
determine if there is communication between Golgi elements in FCHo2 or Mon1a 
silenced cells.  If FCHo2 or Mon1a are required for communication between Golgi 
fragments, then we expect that an individual Golgi element may not recover its 
fluorescence after photobleaching because unquenched fluorescence protein cannot be 
brought into the bleached structure.  Nonspecifically, FCHo2 or Mon1a (5’-UTR) 
silenced GalNAc-T2-GFP expressing cells were imaged with epifluorescence confocal 
microscopy.  A region of the Golgi structure was bleached and fluorescence recovery 
monitored.  In control cells, fluorescence recovery occurred in a matter of seconds 
























Figure 3.7 Golgi fragmentation in FCHo2-depleted cells is cell cycle-dependent  A.  
GalNAc-T2-GFP expressing cells were transfected with siRNA nonspecific, FCHo2, or 
DHC1for 24 h before cell cycle arrest was achieved by 2 mM thymidine treatment for an 
additional 48 h.  Golgi morphology was scored using epifluorescence microscopy with 
representative images shown. B.  Quantifications of four independent experiments are 
graphed showing the percent of Golgi fragmentation with and without thymidine 
treatment. C.  Cells treated with nonspecific, FCHo2, or Mon1a (5’-UTR) oligos for 72 h 
were visualized by live cell microscopy.  Golgi elements (GalNAc-T2-GFP-positive) 












Our previous studies showed that Mon1a plays a role in ER-Golgi traffic (1).  In 
this manuscript, we show that Mon1a is essential for maintaining Golgi integrity.  Our 
previous study showed that Mon1a has a physical interaction with Dynein.  Reductions in 
the levels of Mon1a or Dynein resulted in an impairment of vesicle formation and 
trafficking at the ER, respectively (1).  Here we show that depletion of Mon1a or Dynein 
results in Golgi fragmentation.  Epistasis experiments showed that silencing Rab6 
influenced the Mon1a silencing phenotype, as Rab6 is required for the initial step of 
vesicle formation at the Golgi (12,17).  This result is consistent with Mon1a’s role at the 
ER in efficient vesicle generation.  Interestingly, silencing Rab6 did not prevent the effect 
of reduced Dynein levels on Golgi morphology.  The Golgi remained fragmented when 
Rab6 and Dynein were co-silenced.  We hypothesize that ER-derived vesicle are 
generated at the ER but are not transported appropriately in Dynein silenced cells, 
resulting in Golgi fragmentation. Based on findings that the RNAi phenotypes are 
dependent on the degree of protein reduction, we infer that there is a greater requirement 
for Mon1a at ER-Golgi trafficking then in Golgi maintenance.  
We identified FCHo2 as a Mon1a interacting protein.  Silencing of Mon1a or 
FCHo2 results in Golgi fragments that remain centrally clustered likely around the 
microtubule-organizing center, the canonical site of Golgi assembly.  In contrast, Dynein 
silencing leads to dispersed severely fragmented Golgi fragments (1).  The effects of 




activity of Rab6, but the effects of FCHo2 reduction are cell cycle-dependent.  FCHo2 is 
a member of a large family of proteins known as F-BAR domain-containing proteins that 
are found in all eukaryotes, plants being the only exception.  It is thought that 21 F-BAR 
genes encode about 36 proteins in humans, the majority of which have been demonstrated 
to function in endocytosis.  FCHo2 was shown to bind to the plasma membrane and 
recruit protein machinery required for the formation of clathrin-coated pits, an initial step 
in endocytosis. This role in endocytosis requires the F-BAR domain of FCHo2 and its 
membrane bending capacity, suggesting that FCHo2 deforms the plasma membrane to 
initiate the site of clathrin-coated vesicle formation (10,21,22,28,29).  Membrane bilayers 
that facilitate compartmentalization in all eukarya require protein machinery that can 
deform and induce membrane curvature that mediates organelle shaping and vesicle 
formation supporting intracellular communication (15,21,28-30).  Members of the F-
BAR domain family, including FCHo2, have been demonstrated to perform membrane 
tubulating activities in vivo and in vitro.  The F-BAR domain is formed through an 
antiparallel dimerization of the amino-terminus of two FCHo2 proteins creating a curved 
module lined with positively charged residues that are thought to interact with the 
negatively charged phospholipid headgroups of membrane bilayers, ultimately 
facilitating membrane tubulation (28). 
We hypothesize that FCHo2 is required to reform the Golgi ribbon after mitosis 
because prevention of mitosis through cell cycle arrest significantly decreases the Golgi 
fragmentation observed in FCHo2 silenced cells.  This role is consistent with the 
identified role of FCHo2 as a membrane deforming protein (10,22).  FCHo2 binding to 




which has been shown to be found at the plasma membrane but also at Golgi stacks (31).  
We have not yet identified FCHo2 at the Golgi ribbon, although the interaction is likely 
transient.  We believe that FCHo2’s capacity for membrane tubulation is focused at Golgi 
cisternae promoting Golgi reassembly and ribbon formation after mitotic events.  Data 
showing that the loss of FCHo2 prevents the lateral transfer of Golgi membrane and 
material suggest that FCHo2 is required for Golgi ribbon formation, although the exact 
step of FCHo2 action remains to be clarified. 
The sole Mon1 protein in yeast and nematodes is involved in endocytosis 
(4,5,7,32).  In mammals, Mon1b appears to have retained the original function and has 
been shown to act at the transition from early to late endosomes (2,3).  Mon1b was shown 
to inhibit Rabex5 an activator of Rab5, which displaced Rab5 from early endosomes.  
Subsequently, Mon1b was shown to be able to recruit Rab7 to endosomal surfaces 
through an interaction with the HOPS complex.  Notably, both in overexpression and 
RNAi studies, Mon1a was only shown to have effects on endosomal maturation in 
combination with Mon1b and never by itself.  Further, Mon1b was shown to interact with 
several subunits of the HOPS complex but Mon1a did not.  Our studies have shown that 
loss of Mon1a had no effect on endocytosis but instead affected trafficking in the 
secretory pathway (1).  While we can point to specific steps requiring Mon1a activity, we 
do not at this point know its precise biochemical function.  Here we demonstrate that both 
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 The generation of the eukaryotic endomembrane system allowed biochemical 
processes to be compartmentalized with sophisticated spatial and temporal regulation (1-
8).  The endomembrane system required the development of protein machinery that 
allowed for the intracellular communication between these membrane-bound organelles.  
Significant strides have been made in understanding and identifying this machinery 
through model organisms, genetic screens, and biochemical techniques yet much of the 
actors and their roles in this system remain to be elucidated (9-12).  Characterizing the 
endomembrane system and the proteome that regulates it is a central theme in cellular 
and molecular biology.  The work described in this thesis addresses the characterization 
of a gene product, Mon1a, and the role it plays in membrane traffic and organelle 
maintenance within the mammalian secretory pathway.   
 
4.1 Mon1a function in the secretory pathway 
 The fidelity of the secretory pathway relies on highly regulated trafficking of 
transport vesicles and their contents from a donor to an acceptor compartment (1-
3,9,10,13-15).  The cell biology axiom of ER-Golgi-PM outlining the secretory pathway 




molecular motors.  Genetics first done in S. cerevisiae began to describe the mechanisms 
of membrane traffic in that cytosolic coat proteins are recruited to membrane surfaces via 
GTPases to initiate coat cage assembly and vesicle formation.  Cytoskeletal motors then 
can interact with newly formed vesicles to transport them along cytoskeletal tracks to the 
next organelle depot (9-11).  The original identification and characterization of Mon1 
was performed in yeast where Mon1 was shown to function within the endocytic pathway 
at the vacuole (20,21).  Recent studies on Mon1a, its homologue Mon1b, and nematode 
SAND1 have suggested that their function is evolutionarily conserved and is needed for 
proper maturation of endosomal compartments in higher eukaryotes (17-19).  Yeast 
strains deleted for Mon1 present a range of phenotypes that include vacuole 
fragmentation, increased zinc sensitivity, and vacuolar hydrolase missorting (20,21).   
The original characterization of mammalian Mon1a analyzed the regulation of 
iron stores in mice (22).  This work demonstrated that the C57BL strains of mice carried 
an intrinsic “gain-of-function” mutation in Mon1a that results in more efficient 
trafficking within the secretory pathway, ultimately affecting cellular iron reserves.  The 
authors provided evidence that C57BL mice have less iron in their cells as a direct result 
of having increased levels of the iron exporter ferroportin at the cell surface compared to 
other mouse strains.  They went on to show that Mon1a function was not unique to 
ferroportin trafficking but affected all soluble and membrane-bound proteins that enter 
the secretory pathway.  The aim of the second chapter of this thesis was to clarify the role 
of Mon1a in the secretory pathway in greater detail. 
Biochemical and siRNA analysis revealed that Mon1a function affected the 




cytosolic protein that is recruited to membrane surfaces.  Cell fractionation studies using 
epitope-tagged Mon1a associated with organelles of the early secretory pathway, 
migrating coincidently with ER markers and to a lesser extent with the Golgi.  Mon1a 
protein suppression through siRNA treatment demonstrated that Mon1a was required for 
efficient trafficking of proteins through the secretory apparatus at both early and late 
transport events.  Mass spectrometry and co-immunoprecipitation analysis demonstrated 
that Mon1a interacts with the microtubule-based motor Dynein, a protein known to be 
required in ER-Golgi trafficking.  Both Mon1a and Dynein were found in the same 
vesicle fractions after differential centrifugation.  Further, using a cell culture-based 
vesicle budding protocol adapted from the Schekman group, Mon1a silencing was shown 
to significantly inhibit the formation of ER-derived vesicles, ultimately disrupting 
anterograde transport (16).  These data support a model where Mon1a is recruited to the 
ER surface to aid in vesicle formation.  Dynein subsequently interacts with Mon1a to 
transport the vesicle from the ER to the Golgi apparatus, resulting in efficient anterograde 
trafficking. 
 
4.2 Organelle maintenance 
 The Golgi apparatus is the hub of endomembrane membrane traffic where the 
endocytic and biosynthetic pathways converge (3,5,12,23).  Newly synthesized proteins 
and lipids reach their appropriate destinations through highly regulated membrane 
trafficking networks that ensure the identity and fidelity of the endomembrane system.  
The content of the second chapter defines a role for Mon1a in early anterograde 




Golgi transport of ER-derived vesicles (16).  Protein depletion of Mon1a or Dynein by 
RNAi inhibits ER-Golgi trafficking; however, silencing of Dynein results in complete 
fragmentation of the Golgi apparatus.  Disruption of trafficking at the ER-Golgi interface 
usually has dramatic effects on Golgi morphology as when tether proteins are suppressed 
by siRNA (24,25,27). 
RNAi studies and protein interaction analysis in cell culture were used to 
characterize Mon1a activity in membrane traffic and organelle maintenance in the 
secretory pathway in the third chapter.  A yeast two-hybrid screen found that Mon1a 
interacts with a F-BAR domain-containing protein FCHo2 that has been described to 
function in trafficking at the cell surface in clathrin-mediated endocytosis (28-32).  The 
interaction between Mon1a and FCHo2 was confirmed by co-immunoprecipitation 
studies, yet whether this interaction is direct or indirect is not clear.  Notably, the Golgi 
fragments in cells depleted for FCHo2 by RNAi.  Therefore, new siRNA’s targeting 
Mon1a were created to address the discrepancy in phenotypes between Mon1a and its 
interacting partners.  siRNAs targeting the 5’-UTR of the Mon1a gene resulted in a 
fragmented Golgi phenotype strikingly similar to FCHo2 silenced cells.  Further, the 
fragmented Golgi phenotypes required the activity of the Golgi GTPase Rab6 as co-
silencing suppressed fragmentation, suggesting that Rab6 function is epistatic to both 
Mon1a and FCHo2. 
FCHo2 is a member of a large family of proteins named after a conserved domain 
that defines the family, the F-BAR domain (28-32).  In Chapter 3, we describe a novel 
function for FCHo2 at the Golgi apparatus in the formation of Golgi ribbons following 




down into individual stacks and ultimately vesiculated to allow Golgi material to be 
allocated between the daughter cells (13,23,27,34-36).  After mitosis, the Golgi is 
reassembled into mini-stacks that are laterally fused to create Golgi ribbons, presumably 
a membrane tubulating activity.  Consequently, cells overexpressing F-BAR domain 
proteins, including FCHo2, have extensive membrane tubulation (28-30).  We therefore 
hypothesized that after mitosis, FCHo2 is required to create Golgi ribbons, which 
laterally link individual stacks.  The cell cycle was arrested in silenced cells preventing 
mitotically induced Golgi fragmentation, which tested our model.  The data confirmed 
our hypothesis as cell cycle arrest suppressed Golgi fragmentation in FCHo2-depleted 
cells.  Further, FRAP analysis demonstrated that FCHo2 is needed for lateral diffusion of 
Golgi material as photobleached Golgi regions were unable to recover fluorescence 
providing evidence of FCHo2’s role in Golgi ribbon formation. 
These data suggest that FCHo2 and Mon1a activity are required for maintenance 
of Golgi architecture.  Mon1a and FCHo2 siRNA phenotypes are similar but not identical 
as both fragment the Golgi and require the activity of the Golgi GTPase Rab6.  Golgi 
fragmentation in FCHo2-silenced cells, however, is cell cycle-dependent where the 
Mon1a phenotype is not.  We have yet to identify FCHo2 at the Golgi ribbon, which we 
believe to be a transient interaction that is cell cycle-regulated.  FCHo2 is recruited to the 
cell surface through an association with Ptd(4,5)P(2) (31).  This novel role for FCHo2 in 
Golgi ribbon formation does not conflict with the identified activity of FCHo2 at the cell 
surface in endocytosis and perhaps Ptd(4,5)P(2) mediates recruitment of FCHo2 to Golgi 
cisternae to aid in ribbon formation.  Studies are ongoing to clarify the biochemical 




4.3 Future directions 
Our data have identified roles for Mon1a and FCHo2 in membrane traffic and 
Golgi maintenance, but more work is needed to understand the mechanisms of these 
actions (16).  During the course of this work, several interesting results emerged that 




4.4 Mitochondrial maintenance in FCHo2-depleted cells 
 The Golgi complex is systemically broken down in mammalian cells as they enter 
mitosis to aid the dispersal of Golgi material between daughter cells (35-39).  Another 
tubular organelle that follows a cell cycle-regulated breakdown and reassembly is the 
mitochondria (40-44).  These morphological similarities in the Golgi and mitochondria 
prompted us to examine the structural status of mitochondria in FCHo2-silenced cells.  
Mitochondria were visibly disrupted in cells depleted of FCHo2, which demonstrated a 
role for FCHo2 in the maintenance of both mitochondria and Golgi architecture (Figure 
4.1).  Our data demonstrated that Golgi fragmentation in FCHo2-depleted cells is cell 
cycle- and Rab6-dependent.  Whether the FCHo2 silencing-induced mitochondria 
phenotype is cell cycle- or Rab6-regulated remains to be demonstrated.  Further, the 
functional significance of the Mon1a-FCHo2 interaction in Golgi and/or mitochondrial 
maintenance remains to be demonstrated.  Currently, we are using protein truncations of 
Mon1a to map the FCHo2-binding domain so that RNAi and rescue studies can be 
performed to address the functional significance of this interaction in membrane traffic 




Figure 4.1 FCHo2 silencing fragments mitochondria Confocal images of nonspecifically 
and FCHo2 silenced GA=alNAc-T2-GFP expressing cells treated with MitoTracker.  





has been unsatisfactory.  Subcellular localization studies in synchronized cells may be 




4.5 Golgi-ER retrograde trafficking 
We demonstrated that Mon1a is required for anterograde trafficking to the Golgi.  
These data were discussed in Chapter 2.  Subsequently, we have confirmed this result 
independently using co-silencing to demonstrate epistatic relationship between proteins 
involved in ER-Golgi transport.  Golgi morphology was assessed in cells depleted of both 
Mon1a and the cis-Golgi tether p115 required in anterograde transport.  It has been 
reported in the literature that siRNA-dependent silencing of p115 fragments the Golgi 
due to lack of tethering activity at the Golgi.  Mon1a functions upstream of p115 at the 




Mon1a and p115 suppressed Golgi fragmentation (Figure 4.2) providing further evidence 
for Mon1a function in Golgi-ER transport as well as acting as a positive control for these 
epistasis experiments. 
We next considered whether Mon1a is involved in the reciprocal retrograde 
pathway.  Both Mon1a and Rab6 recruit and interact with the motor Dynein to efficiently 
traffic vesicles to the appropriate organelle (15,16,27).  One hypothesis follows that 
Mon1a is needed at the Golgi to aid in Rab6-dependent retrograde Golgi-ER trafficking 
and it would follow that Mon1a silencing might suppress ZW10 knockdown-dependent 
Golgi fragmentation.  To address this possibility and determine the epistatic relationship 
of Mon1a and ZW10, co-silencing experiments were performed.  RNAi targeting Mon1a 
(ORF) significantly depletes Mon1a protein but leaves Golgi morphology intact (16).  It 
is thought that Golgi fragmentation in ZW10-silenced cells is a result of Rab6-dependent 
retrograde transport of Golgi-derived vesicles and subsequent lack of tethering activity at 
the ER, similar to p115 at the Golgi (27).  Inhibiting retrograde transport upstream at the 
Golgi by depleting cells of Rab6 and subsequent vesicle formation suppresses the 
fragmented phenotype.  Mon1a is required for anterograde transport at the ER in vesicle 
formation similar to Rab6 activity at the Golgi (16).  Co-silencing of Mon1a and ZW10 
also suppressed ZW10 knockdown-dependent Golgi fragmentation (Figure 4.2).  We 
conclude from these data that Mon1a and Rab6 activity is required for Golgi 
fragmentation seen in ZW10-depleted cells.  These data suggest a role for Mon1a in 
Rab6-dependent retrograde trafficking.  
Functional data, however, are required to demonstrate that Mon1a is required in 




Figure 4.2 Co-silencing of Mon1a and tethers suppresses Golgi fragmentation GalNAc-
T2-GFP-expressing cells were transfected with siRNAs to Rab6, Mon1a, p115, and 




surface, is internalized, and traffics to the ER via the Golgi apparatus traversing the entire 
retrograde pathway (45-48).  Use of fluorophore-tagged CTxB in Mon1a-depleted cells 
will address the role of Mon1a in Rab6-dependent retrograde transport.  Further, a role 
for FCHo2 in retrograde trafficking at the Golgi apparatus has yet to be addressed.  
Vesicle formation at the cell surface (towards the cytoplasm) where FCHo2 was 
originally described to function is topographically similar to vesicle budding at the Golgi. 
FCHo2 activity in retrograde transport can be addressed using RNAi analysis and CTxB 




4.6 Consequences of the allelic status of Mon1a 
 Mon1a was originally identified in mice in a quantitative trait locus (QTL) 
analysis that identified modifiers of the iron overload disorder hemochromatosis (22).  
That work identified a missense mutation in the Mon1a gene in C57BL mice that resulted 
in a “gain-of-function” allele that was capable of moving proteins through the secretory 
pathway more efficiently.  Increased Mon1a activity in C57BL mice resulted in increased 
cell surface ferroportin levels and subsequent cellular and splenic iron reduction.  To 
address the “gain-of-function” allele ex vivo, interlukin-12 (IL-12) levels were measured 
from splenocytes treated with LPS isolated from different strains of mice.  Splenocytes 
from C57BL/6 mice showed significantly increased IL-12 secretion at all time points 
measured compared to the other strains (Figure 4.3).  SWR and congenic mice with a 
wild type allele of Mon1a secreted less IL-12 than C57BL/6 mice demonstrating “gain-
of-function” activity of this allele.  The allelic status of Mon1a could have significant 
ramifications on several biological processes, including the inflammatory response and 
pathogen clearance.  Characterizing Mon1a in disease models could yield important 
insights to our understanding of membrane traffic in disease progression.  Protein 
interaction studies comparing the binding partners of the Mon1a alleles could identify 
protein partners specific to an allele of Mon1a that could help us understand the 





Figure 4.3 In vivo analysis of cytokine secretion in LPS treated splenocytes Splenocytes 
isolated from mice were treated with LPS and IL-12 analysis was determined by ELISA 
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